Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: January 25, 2024
Event: Implementation of a 1-for-12 reverse stock split of common stock, effective January 26, 2024, at 5:00 p.m. Eastern Time. The split was approved by stockholders at the Annual Meeting on December 13, 2023.
Key Financial Metrics
This filing focuses on capital structure changes rather than operational financial performance. However, it provides historical loss data adjusted for the reverse split:
- Net Loss (12 months ended June 30, 2023): $(10,631,720)
- Net Loss (12 months ended June 30, 2022): $(8,306,051)
- Net Loss (3 months ended Sept 30, 2023): $(2,425,204)
- Net Loss (3 months ended Sept 30, 2022): $(1,208,293)
- Shares Outstanding (Pre-Split, Jan 25, 2024): ~17,930,673
- Shares Outstanding (Post-Split): ~1,494,223
- Authorized Shares: 100 million (unchanged)
Note: The filing text does not provide current revenue, cash flow, debt, or liquidity figures.
Material Changes
- Share Count Reduction: Outstanding shares reduced from approximately 17.9 million to 1.5 million.
- Loss Per Share Adjustment: Historical loss per share figures have been restated on a post-split basis. For the 12 months ended June 30, 2023, the loss per share increased from $(10.58) to $(127.00) due to the reduced share count.
- Derivative Adjustments: Proportionate adjustments made to exercise prices and share counts for outstanding stock options, RSUs, and warrants.
- Warrant Reset: Series E Warrants include a one-time reset feature where the exercise price will be adjusted to the lesser of the then-current price or 90% of the five-day VWAP following the split.
- Trading Details: Trading symbol remains "INBS" on Nasdaq Capital Market. New CUSIP: 36151G600. Trading on a split-adjusted basis began January 29, 2024.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the reverse split to effectuate the amendment to the Certificate of Incorporation. No forward-looking guidance regarding revenue or profitability is provided in this document.
Contingencies and Unusual Items:
- Fractional Shares: No fractional shares will be issued; holders entitled to fractions will receive rounding up to the nearest whole share.
- Warrant Terms: The specific reset mechanism for Series E Warrants is a material term change triggered by this event.
Investor Verification Checklist
- Verify the new CUSIP number (36151G600) for trading and settlement purposes.
- Confirm the adjusted exercise prices and share counts for any held options, RSUs, or warrants.
- Review the specific terms of the Series E Warrant reset feature to understand potential dilution or cost basis changes.
- Check the post-split share count (~1.5 million) against the company's minimum bid price requirements for Nasdaq compliance.